OncoCyte (OCX) Q1 2025 Earnings Call May 12, 2025 05:00 PM ET Company Participants Josh Riggs - President & Chief Executive OfficerAndrea James - Chief Financial OfficerEkkehard Schütz - Chief Science OfficerYuan Zhi - Managing Director Conference Call Participants Mark Massaro - MD & Senior Equity Research AnalystMason Carrico - Research AnalystThomas Flaten - Senior Research AnalystMike Matson - Senior Equity Research Analyst Operator Welcome everyone and Welcome, everyone, and thank you for joining us to ...

OncoCyte (OCX) Q1 2025 Earnings Call May 12, 2025 05:00 PM ET Speaker0 Welcome everyone and Welcome, everyone, and thank you for joining us to discuss OncoCyte's first quarter twenty twenty five results. If you have not seen today's shareholder letter, please visit OncoCyte's Investor Relations page at investors.oncoCyte.com. Today's prepared remarks build upon the information already shared in this robust letter. Joining us today are OncoCyte President and CEO, Josh Riggs Chief Science Officer, Ecky Schutz ...

Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are now using our GraftAssure research-use-only kitsTo reflect our larger market opportunity, we plan to rename the company in Q2 IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with i ...